Research programme: proteolytic bacterial enzymes - Hansa Medical

Drug Profile

Research programme: proteolytic bacterial enzymes - Hansa Medical

Alternative Names: Endoglycosidase of Streptococcus pyogenes; EndoS; Second generation IdeS; Second generation Ig-G-degrading enzyme of Streptococcus pyogenes

Latest Information Update: 10 Apr 2015

Price : $50

At a glance

  • Originator Hansa Medical AB
  • Class Bacterial proteins; Enzymes
  • Mechanism of Action Immunoglobulin modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders
  • Research Transplant rejection
  • Discontinued Rheumatoid arthritis; Streptococcal infections

Most Recent Events

  • 10 Apr 2015 Early research in Transplant rejection (Prevention) in Sweden (Parenteral)
  • 05 Feb 2013 The Swedish Medical Products Agency approves clinical trial application for IdeS in Healthy volunteers
  • 30 Mar 2012 Discontinued - Preclinical for Rheumatoid arthritis in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top